Dr Natalie Gauld is a pharmacist and reclassification consultant at Natalie Gauld Ltd. She is an Honorary Research Fellow at the Department of General Practice and Primary Health Care, University of Auckland, New Zealand. She has received funding for reclassifications including trimethoprim, vaccinations, calcipotriol, adapalene, sildenafil and oral contraceptives. She was on the Medicines Classification Committee in NZ (2004-2009). She has consulted to Green Cross Health, the pharmaceutical industry and pharmacy organisations. She has received travel funding for speaking engagements at conferences from industry and pharmacy organisations. She received unrestricted research grants from Green Cross Health, the Pharmacy Guild, the Pharmaceutical Society of NZ and ProPharma for the trimethoprim research. She is a member of the National Executive of the Pharmaceutical Society of NZ. The opinions expressed in this article are the author’s, and not as a representative of any organisation.
The reclassification of Viagra from a ‘prescription-only’ to a ‘pharmacy’ medicine gives pharmacists the chance to show how well they can manage its supply, writes Natalie Gauld.
After a dwindle in the number of reclassifications of prescription-only to pharmacy medicines in the UK, things are starting to look up, writes Natalie Gauld.
In August 2016, pharmacists in New Zealeand were given permission to supply adapalene without a prescription through reclassification. This is in line with both Singapore (approval March 2016) and the United States (approval July 2016). For New Zealand and the United States, a major consideration was potential teratogenicity, with both countries considering non-prescription status was appropriate based on the evidence. Interestingly, Germany took a different approach, rejecting the ada